Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ViewRay, Inc. (NASDAQ: VRAY).

Full DD Report for VRAY

You must become a subscriber to view this report.


Recent News from (NASDAQ: VRAY)

ViewRay: Buy The Secondary
Shares of ViewRay ( VRAY ) are trading just above its IPO price point from back in 2015. Year to date, the stock is in the green by about 8%. Interestingly enough, the stock rose by as much as 75% from recent lows before pulling back in August. Chart Figure 1: VRAY daily advanced ch...
Source: SeekingAlpha
Date: August, 22 2018 21:55
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
CLEVELAND , Aug. 17, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offer...
Source: PR Newswire
Date: August, 17 2018 16:15
ViewRay prices stock offering
ViewRay (NASDAQ: VRAY ) has priced public offering of 16,216,217 common stock at $9.25 per share, for gross proceeds of $150M. The offering is expected to close on or about August 17. More news on: ViewRay, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 15 2018 05:38
ViewRay Announces Pricing of Public Offering of Common Stock
CLEVELAND , Aug. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 16,216,217 shares ...
Source: PR Newswire
Date: August, 14 2018 23:04
After Hours Gainers / Losers (08/14/2018)
Top Gainers: PETQ +12.2% . EGN   +7.7%.   PRSP   +5.3% .  OTCPK:APNR +4.0% . FOMX   +2.1% . More news on: PetIQ, Energen Corporation, Perspecta, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 17:36
ViewRay Announces Proposed Public Offering of Common Stock
CLEVELAND , Aug. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $125.0 mil...
Source: PR Newswire
Date: August, 14 2018 16:23
ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2018 Results - Earnings Call Transcript
ViewRay, Inc. (VRAY) Q2 2018 Earnings Conference Call August 03, 2018, 08:30 ET Executives Lee Roth - SVP, The Ruth Group, Inc. Scott Drake - President & CEO Ajay Bansal - CFO Analysts Difei Yang - Mizuho Securities Craig Bijou - Cantor Fitzgerald & Co. Andrew ...
Source: SeekingAlpha
Date: August, 05 2018 02:27
ViewRay reports Q2 results
ViewRay ( VRAY ) Q2 results : Revenues: $16.4M; Product: $15.4M; Service: $1M (+66.7%); Distribution Rights: $0.1M (unch). More news on: ViewRay, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 03 2018 08:20
ViewRay misses by $0.10, beats on revenue
ViewRay (NASDAQ: VRAY ): Q2 EPS of -$0.30 misses by $0.10 . More news on: ViewRay, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 03 2018 07:31
ViewRay Reports Second Quarter 2018 Financial Results
CLEVELAND , Aug. 3, 2018 /PRNewswire/ --   ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights: Total revenue of $16.4 million, primarily from 3 revenue units, up from $...
Source: PR Newswire
Date: August, 03 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-076.516.296.596.16511,298
2018-12-066.306.416.516.015765,544
2018-12-056.996.337.006.30871,625
2018-12-046.996.327.006.305750,142
2018-12-036.846.977.056.74873,452

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0760,109117,67651.0801Short
2018-12-06109,271187,77858.1916Short
2018-12-04101,204290,59434.8266Cover
2018-12-03114,907276,56841.5475Short
2018-11-3071,600167,45442.7580Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRAY.


About ViewRay, Inc. (NASDAQ: VRAY)

Logo for ViewRay, Inc. (NASDAQ: VRAY)

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing a simultaneous MRI guided adaptive radiation therapy technology for the treatment of cancer. With the ViewRay system, physicians have more control over the delivery of their radiation therapy prescriptions. ViewRay technology provides continuous soft tissue imaging during treatment, using MRI guided radiation therapy, so that clinicians can see the target, monitor the radiation dose, and adapt to changes in the patient s anatomy all in real time.

 

 

 

Current Management

  • Dinara Akzhigitova / Principal Executive Officer, President, Principal Fin. Officer, Secretary
    • DINARA AKZHIGITOVA, , has acted as our President, Treasurer and sole Director since our incorporation on September , . Akzhigitova Dinara graduated the State UnDINARA AKZHIGITOVA, , has acted as the Company s President, Treasurer and sole Director since our incorporation on September , . Akzhigitova Dinara graduated the State University of Tver, Russia in . Ms. Akzhigitova has a degree in software engineering and in finance.iversity of Tver, Russia in . Ms. Akzhigitova has a degree in software engineering and in finance.
  • Chris A. Raanes / President, CEO
    • Mr. Raanes brings over years of experience in the private and public medical device field. As our President and Chief Executive Officer, Mr. Raanes has supported our growth and strategic initiatives, including our worldwide commercial expansion of MRIdian. Previously, Mr. Raanes was Executive Vice President from July to November and Chief Operating Officer and Senior Vice President from September to July at Accuray Incorporated, a medical device company. He also served as Vice President and General Manager, Digital Imaging at PerkinElmer Inc., a healthcare company, from December to March . Mr. Raanes holds a B.S. and an M.S. in Electrical Engineering from the Massachusetts Institute of Technology. We believe Mr. Raanes is qualified to serve on our board of directors because of his extensive management experience and his expertise in radiation therapy device commercialization and operations.
  • Douglas H. Keare / COO
    • Mr. Keare has over twenty years of technology and medical device executive experience. Before joining ViewRay, Mr. Keare founded and served as CEO of RallyOn, Inc., a software company focused on corporate health and wellness, from October to December . Prior to that, Mr. Keare served as Vice President of Customer and Technical Support at Accuray Inc. from December to January . Mr. Keare also served as the President and Chief Operating Officer for Pricing Dynamics from July to July . He held several positions at ADAC Laboratories in Customer Support, Operations and Quality from October to March . As Vice President of Quality, he led ADAC s successful effort to win the Malcolm Baldridge National Quality Award in . Mr. Keare received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University s Graduate School of Business.
  • D. David Chandler / CFO
    • Mr. Chandler has over years of experience in finance, strategic planning, investor relations and accounting. Before joining ViewRay, Mr. Chandler served as a Practice Manager and consulting Chief Financial Officer with vcfo Holdings, Inc., a financial consulting firm, from October to November . Prior to that, he served as Chief Operating Officer and Chief Financial Officer of Straitshot Communications, Inc., a network solutions company, from June to July and Chief Financial Officer of Stellar One Corporation, a technology company, from July to April . Prior to Stellar One Corporation, Mr. Chandler held a variety of financing and accounting management roles, including Business Assurance Manager with PricewaterhouseCoopers LLP. Mr. Chandler received a B.A. in Business from the University of Washington, Michael G. Foster School of Business and a B.A. in German from the University of Washington.
  • James F. Dempsey / CSO
    • Dr. Dempsey has been a member of the board of directors since January . Dr. Dempsey brings more than years of experience in the field of radiotherapy medical physics to ViewRay. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July to July and Associate Professor from July to January . Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis. We believe Dr. Dempsey is qualified to serve on our board of directors based on his indepth knowledge of our product, business and industry, as well as his expertise in nuclear chemistry and physics and medical physics.
  • Joshua Bilenker / Dr. Bilenker joined Aisling Capital LLC in April and has served as an Operating Partner since November . He has served as Chief Executive Officer of Loxo Oncology, Inc., an Aisling Capital LLC portfolio company, since July . Previously, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the FDA from August to April . Dr. Bilenker has served on the boards of directors of Loxo Oncology, Inc. since July , T Biosystems, Inc. since August and Roka Bioscience, Inc. since January , as well as on the boards of directors of several private companies. He is also a board member of the NCCN Foundation and BioEnterprise. Dr. Bilenker holds an A.B. in English from Princeton University and an M.D. from the Johns Hopkins School of Medicine. We believe Dr. Bilenker is qualified to serve on our board of directors based on his oncology background, experience at the FDA and his extensive service as a director or officer of, and as an investor in, other healthcare companies.
  • David Bonita / Dr. Bonita has served as a Private Equity Partner at OrbiMed Advisors LLC, or OrbiMed, since June . Dr. Bonita joined OrbiMed in June as a Private Equity Senior Associate, and was promoted to Private Equity Principal in December . Prior to OrbiMed, he was a corporate finance analyst in the healthcare investment banking group of Morgan Stanley amp Co. from February to July , and a corporate finance analyst in the healthcare investment banking group of UBS AG from August to February . Dr. Bonita has also served on the board of directors of Loxo Oncology, Inc. since October , as well as on the boards of directors of several private companies. Dr. Bonita holds an A.B. in Biological Sciences from Harvard College and an M.D. and M.B.A. from Columbia University in the City of New York. We believe Dr. Bonita is qualified to serve on our board of directors due to his extensive investment experience in the healthcare industry.
  • Caley Castelein / Dr. Castelein has served as a Managing Director of Kearny Venture Partners, L.P. since September . Prior to that, Dr. Castelein served as a Managing Director at Thomas Weisel Partners, which was acquired by Stifel, Nicolaus amp Company, Incorporated in July , from March to September . Dr. Castelein has served on the boards of directors of several private companies. Dr. Castelein holds an A.B. in Biological Sciences from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry.
  • James F. Dempsey / Dr. Dempsey has been a member of the board of directors since January . Dr. Dempsey brings more than years of experience in the field of radiotherapy medical physics to ViewRay. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July to July and Associate Professor from July to January . Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis. We believe Dr. Dempsey is qualified to serve on our board of directors based on his indepth knowledge of our product, business and industry, as well as his expertise in nuclear chemistry and physics and medical physics.
  • Mark S. Gold / Dr. Gold was a Professor, Distinguished Professor and Chairman of Psychiatry at the University of Florida from until his retirement in June . Dr. Gold has worked for over years in basic science and clinical research, translating research into clinical practice. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. He was a Founding Director of the Somerset Valley Bank and Somerset Valley Financial from to . Dr. Gold has served on the board of directors of Axogen, Inc. formerly LecTec Corporation since September . Dr. Gold is currently the Chairman of RiverMend Health. We believe Dr. Gold is qualified to serve on our board of directors because of his academic expertise and his extensive research experience across medical specialties and institutions.
  • Aditya Puri / Mr. Puri has served as an Investments Director at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, since October . Previously, he was a Director in Khazanah Nasional s Life Sciences unit since November , which was responsible for Khazanah s life sciences investments. Prior to that, Mr. Puri consulted part time in the greater Boston area for various healthcare and cleantech startups affiliated with Harvard University and Massachusetts Institute of Technology, or MIT, from to . Mr. Puri also served as Managing Director of global development at Salary.com from July to April . Mr. Puri was at the Yankee Group, a global technology research and consulting company, from September to March , finishing his tenure as a VicePresident and member of the leadership team. Between March and April , he was at Boston Scientific, a Fortune medical device manufacturer. Mr. Puri serves on several boards of directors of private companies in the investment and healthcare fields. Mr. Puri has a B.S. from the University of Southern Maine and received an M.B.A. from the MIT Sloan School of Management. We believe Mr. Puri is qualified to serve on our board of directors because of his extensive experience in life sciences investment and growth.
  • Brian K Roberts /

Current Share Structure

  • Market Cap: $535,924,382 - 03/12/2018
  • Authorized: 300,000,000 - 03/30/2016
  • Issue and Outstanding: 67,454,296 - 11/03/2017
  • Float: 3,643,480 - 03/30/2016

 


Recent Filings from (NASDAQ: VRAY)

Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 11 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 10 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: May, 10 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: May, 10 2018

 

 


Daily Technical Chart for (NASDAQ: VRAY)

Daily Technical Chart for (NASDAQ: VRAY)


Stay tuned for daily updates and more on (NASDAQ: VRAY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VRAY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRAY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRAY and does not buy, sell, or trade any shares of VRAY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/